Clinical Trial

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2022-04-08; most recent amendment 2026-02-26.
Trial Details
NCT Number NCT05325632
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: ImmunoRestoration
Conditions HER2-positive Breast Cancer
Enrollment 53 participants
Start Date 2021-10-28
Primary Completion 2027-02 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-02